Foghorn Therapeutics is cutting 40% of its workforce after Eli Lilly ends cancer drug partnership
The companies are scrapping two collaborative cancer programs and don't anticipate any further joint projects
The companies are scrapping two collaborative cancer programs and don't anticipate any further joint projects